n.50 – ROLE OF 11C ACETATE PET/CT IN PATIENTS WITH SUSPECTED RELAPSE OF PROSTATE CANCER



Abstract

BACKGROUND-AIM
The reliability of 11C Acetate as tracer for prostate cancer remains an object of debate for clinicians.
AIM OF THE STUDY was to evaluate the accuracy of 11C Acetate PET/CT in restaging patients with previous history of prostate adenocarcinoma who faced biochemical relapse after early radical treatment.
METHODS
We retrospectively evaluate 138pts (mean age 70 ± 7 y), with biochemical suspect of relapse, who underwent 11C Acetate PET/CT
RESULTS
RESULTS: PET/CT scan was positive in 95 pts (69%). Receiver operating characteristic (ROC) analysis showed that the highest accuracy (sensitivity 73 %, specificity 79%) was achieved when prostate-specific antigen (PSA) value of 1.87 ng/ml was used as cutoff value for interpreting the results (p <0.0001 and the area under the ROC curve AUC = 0.833). All pts treated with radiotherapy showed a positive PET/CT scan. The cutoff value for pts treated with prostatectomy was 2.25 ng/ml (sensitivity 60%, specificity 81%). However, in this last group analyzing only pts out-off androgen-deprivation therapy the cutoff decreased at 1.87 ng/ml (sensitivity 75%, Specificity 87%).
CONCLUSION
11C Acetate PET/CT is a useful tool in patients affected by prostate cancer with suspected relapse due to PSA elevation. The highest accuracy is reached evaluating pts with previous prostatectomy, without androgen-deprivation therapy and PSA cutoff level of 1.87 ng/ml.

Scarica PDF